Traws Pharma, Inc. Proceeds from Issuance of Private Placement
Traws Pharma, Inc. (TRAW) reported Proceeds from Issuance of Private Placement of $14.00 million for the 9-month period ending 2024-09-30, per its 10-Q filed 2025-11-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfPrivatePlacement · last filed 2025-11-13
- Traws Pharma, Inc. proceeds from issuance of private placement for the quarter ending 2024-09-30 was $0.00.
| Period end | Proceeds from Issuance of Private Placement 3 month | Proceeds from Issuance of Private Placement 6 month | Proceeds from Issuance of Private Placement 9 month |
|---|---|---|---|
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $14.00M 10-Q · filed 2025-11-13 | |
| 2024-06-30 | $14.00M 10-Q · filed 2025-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |